Entecavir-based combination therapies for chronic hepatitis B: A meta-analysis

Existing Reviews

Please note, new claims can take a short while to show up.

No claims yet.

Annotation Summary

Term Occurence Count Dictionary
hepatitis A 1 infectiousdiseases
hepatitis B 10 infectiousdiseases
hepatitis C 1 infectiousdiseases
lamivudine 3 infectiousdiseasesdrugs
tenofovir 3 infectiousdiseasesdrugs

Graph of close proximity drug and disease terms (within 200 characters).

Note: If this graph is empty, then there are no terms that meet the proximity constraint.

Review

Having read the paper, please pick a pair of statements from the paper to indicate that a drug and disease are related.

Select Drug Character Offset Drug Term Instance
lamivudine 3077 (interferon-alpha and pegylated interferon-alpha) and HBV polymerase inhibitors (nucleoside analogs: lamivudine [LAM], telbivudine [LdT], and entecavir [ETV] and nucleotide analogs: adefovir [ADV] and tenofovir [TDF]).[[7]]
lamivudine 4168 patients. For example, ETV combination treatment is more potent than ETV monotherapy for patients with lamivudine /adefovir resistance. Because of a further decrease in HBV DNA following the addition of another NA.[[11]]
lamivudine 4803 therapy;[[14]] ETV monotherapy versus other nucleos(t)ide analogs combination therapy, for example, lamivudine and adefovir combination therapy.[[15]] However, no relevant meta-analyses have directly compared ETV
tenofovir 3177 lamivudine [LAM], telbivudine [LdT], and entecavir [ETV] and nucleotide analogs: adefovir [ADV] and tenofovir [TDF]).[[7]] Entecavir is a new cyclopentyl guanosine NUC which is efficiently phosphorylated to the
tenofovir 3650 plus-strand DNA synthesis.[[8]] Entecavir treatment is more favorable compared to other NUCs other than tenofovir , because it has a higher genetic barrier to resistance with more than three sites are required for drug
tenofovir 3865 resistance to develop, and a safer profile. In addition, the efficacy of entecavir is not worse than tenofovir . Therefore, ETV is now recommended as a first choice for CHB patients by most international guidelines.[[9],[10]]Despite
Select Disease Character Offset Disease Term Instance
hepatitis A 6951 treatment. The exclusion criteria were as follows: duplicated data; coinfection with other viruses such as hepatitis A , C, D, or E viruses or human immunodeficiency virus; autoimmune hepatitis, alcoholic liver disease,
hepatitis B 65 Title: MedicineEntecavir-based combination therapies for chronic hepatitis B A meta-analysisAoran LuoXiaoyan JiangHong RenSherief Abd-Elsalam.Key Laboratory of Molecular Biology
hepatitis B 675 and safety of the entecavir (ETV) monotherapy versus the ETV-based combination therapy for chronic hepatitis B .Methods:A comprehensive literature search was performed on the comparison of ETV-based combination therapy
hepatitis B 824 search was performed on the comparison of ETV-based combination therapy and monotherapy for chronical hepatitis B (CHB) patients in the PubMed, Embase, Web of Science, the Cochrane Libraries, and the Chinese BioMedical
hepatitis B 1385 patients (four cohorts, n = 196 patients), and Group C: entecavir-treated patients with undetectable hepatitis B virus DNA (two RCTs and two cohorts, n = 297). Group A. ETV monotherapy was better for rates of
hepatitis B 2204 better than ETV monotherapy. Further studies are needed to verify this conclusion.Introduction1Chronic hepatitis B virus (HBV) infection remains a serious global health problem. Currently, approximately two billion
hepatitis B 2428 been infected with HBV, and approximately 3.6% of the world's population are suffering from chronic hepatitis B (CHB) worldwide.[[1]] Like patients with hepatitis C will develop into end-stage liver disease,[[2]–[4]]
hepatitis B 2681 are expected to develop cirrhosis, liver failure, and/or hepatocellular carcinoma (HCC).[[5]] Chronic hepatitis B cannot be completely cured because the covalently closed circular DNA persists in the nuclei of infected
hepatitis B 5608 following strategy: (((((Lamivudine) OR Tenofovir) OR Adefovir) OR Telbivudine) AND Entecavir) AND (HBV OR hepatitis B ). The search was restricted to “human.” The reference lists of all the retrieved documents were
hepatitis B 13394 in nucleos(t)ide-naive patients and nucleos(t)ide-resistant patients. ETV = entecavir, HBV = hepatitis B virus.Table 2Characteristics of the patients included in this meta-analysis.Four studies including 338
hepatitis B 20439 guidelines. But for nucleos(t)ide-resistant patients or entecavir-treated patients with undetectable hepatitis B virus DNA to maintain treatment effect, it is uncertain that ETV-based combination therapy or ETV monotherapy
hepatitis C 2481 world's population are suffering from chronic hepatitis B (CHB) worldwide.[[1]] Like patients with hepatitis C will develop into end-stage liver disease,[[2]–[4]] 15% to 40% of patients with CHB are expected to

You must be authorized to submit a review.